anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Initiate therapy with ALOPRIM 24 to 48 hours before the start of chemotherapy known to cause tumor cell lysis. Additionally, administer fluids sufficient to yield a daily urinary output of at least two liters in adults with a neutral or, preferably, slightly alkaline urine. 

The recommended daily dose of ALOPRIM is shown in Table 1. Administer the daily dose as single infusion or in equally divided infusions at 6-, 8-, or 12-hour intervals at a rate appropriate for the volume of infusate.

The dosage of ALOPRIM to lower serum uric acid to normal or near-normal varies with the severity of the disease. Monitor serum uric acid levels at least daily and administer ALOPRIM at a dose and frequency to maintain the serum uric acid within the normal range. Discontinue ALOPRIM when the patient is able to take oral therapy or when the risk of tumor lysis has abated.
The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind to human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind to CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds to human CD3 and a second antigen binding molecule that specifically binds to human CD20. In certain embodiments, the bispecific antigen binding molecules of the invention are capable of inhibiting the growth of CD20 expressing B-cell tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful in the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for treating a variety of cancers as well as other CD 20-associated diseases and disorders.
Oxidative stress, fibrosis, and inflammasome activation from advanced glycation end product (AGE)-receptor of advanced glycation end product (RAGE) interaction contribute to diabetic cardiomyopathy (DCM) formation and progression. Our study revealed the impact of β-caryophyllene (BCP) on activating cannabinoid type 2 receptors (CB2Rs) against diabetic complication, mainly cardiomyopathy and investigated the underlying cell signaling pathways in mice. The murine model of DCM was developed by feeding a high-fat diet with streptozotocin injections. After the development of diabetes, the animals received a 12-week oral BCP treatment at a dose of 50 mg/kg/body weight. BCP treatment showed significant improvement in glucose tolerance and insulin resistance and enhanced serum insulin levels in diabetic animals. BCP treatment effectively reversed the heart remodeling and restored the phosphorylated troponin I and sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a expression. Ultrastructural examination showed reduced myocardial cell injury in DCM mice treated with BCP. The preserved myocytes were found to be associated with reduced expression of AGE/RAGE in DCM mice hearts. BCP treatment mitigated oxidative stress by inhibiting expression of NADPH oxidase 4 and activating phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling. Also, BCP suppressed cardiac fibrosis and endothelial-to-mesenchymal transition in DCM mice by inhibiting transforming growth factor β (TGF-β)/suppressor of mothers against decapentaplegic (Smad) signaling. Further, BCP treatment suppressed nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome activation in DCM mice and alleviated cellular injury to the pancreatic tissues evidenced by significant elevation of the number of insulin-positive cells. To demonstrate a CB2R-dependent mechanism of BCP, another group of DCM mice were pretreated with AM630, a CB2R antagonist. AM630 was observed to abrogate the beneficial effects of BCP in DCM mice. Taken together, BCP demonstrated the potential to protect the myocardium and pancreas of DCM mice mediating CB2R-dependent mechanisms. SIGNIFICANCE STATEMENT: BCP, a CB2R agonist, shows protection against DCM. BCP attenuates oxidative stress, inflammation, and fibrosis in DCM via activating CB2Rs. BCP mediating CB2R activation favorably modulates AGE/RAGE, PI3K/AKT/Nrf2β and TGF-β/Smad and (NLRP3) inflammasome in diabetic cardiomyopathy.
PURPOSE: A manufacturing method of an angiotensin converting enzyme(AEC) inhibitor from an old pumpkin is provided, to develop a new high functional food material for the treatment of high blood pressure by using hydrothermal extraction, vacuum concentration, ultrafiltration with a molecular weight limit of 1000 Dalton, gel permeation chromatography(GPC), and reversed-phase high pressure liquid chromatography(reversed-phase HPLC). CONSTITUTION: The pumpkin is washed and cut for gyre extraction at 95°C for 2 hours. The extract is filtered through a filtering paper and concentrated in vacuum by using a rotary vacuum evaporator at 65°C. The dried concentrate is dissolved in 0.01M of phosphate buffer solution (pH7.0) after lyophilization and is centrifuged at 12,000 rpm and 4°C for 30 min. The upper part of the solution after centrifuging is ultrafiltered and the filtered solution is loaded on a gel permeation chromatography(GPC). The column of the GPC uses resin of Sephadex G-15 and the phosphate buffer solution at pH 7.0. The ACE inhibitor is separated from the lung of a rabbit and uses Hippuryl-L-histidyl-L-leucine(HHL) as a substrate.
PURPOSE: The prevalence of comorbid depression and chronic kidney disease (CKD) is high. The aim of this brief report was to review 2 cases of treatment with tranylcypromine (TCP) in patients with treatment-resistant depression (TRD) and CKD. Tests of the plasma concentration of TCP were included.
METHODS: Medical and psychiatric notes of the 2 patients were reviewed with plasma concentrations of TCP as a key aspect of the discussion. The data are evaluated in the context of relevant medical and pharmacokinetic literature.
FINDINGS: Plasma concentrations of TCP are highly variable both in patients with and without CKD. Plasma concentrations of TCP were not increased in the 2 cases with CKD as compared with literature data of patients without CKD. No signs of intoxication were detected in 2 cases with CKD that impaired continuous treatment of depression with TCP.
IMPLICATIONS: TCP may be considered in selected cases of TRD with concomitant CKD. More clinical data and tests of plasma concentrations of TCP are needed in patients with CKD.
Highly active and long lasting cyclic hexapeptide analogs of somatostatin are prepared. A single amino acid of D-configuration, functioning as a spacer for the remaining amino acids, replaces seven of the ring amino acids of somatostatin. The amino acid adjacent to this spacer amino acid is methylated on the nitrogen and is of the D-configuration. The two amino acids on either side of this dipeptide are also of D-configuration. The remaining two amino acids, Trp and Lys are either D- or L-. The order of the amino acids is reversed relative to the sequence found in somatostatin. The structures therefore represent a modified form of D-retro peptide analogs. The cyclic hexapeptides are easier to synthesize, have a longer duration of activity, and many have a greater level of activity than somatostatin. The compounds have the properties of inhibiting the release of glucagon, growth hormone and insulin. Certain of the compounds also are capable of inhibiting the release of gastric acid secretions. The compounds are particularly useful in the treatment of acromegaly, diabetes, diabetic retinopathy and peptic ulcers. These cyclic hexapeptides are prepared by the solid phase method.
Seventy patients undergoing lower limb surgeries were included in this study. Using a random number sequence, patients were enrolled in one of two groups: Group T receiving 5 µg of dexmedetomidine (Precedex® 100 µg/mL, Hospira, Inc., IL, U.S.A.) combined with 12.5 mg of 0.5% hyperbaric bupivacaine (Marcaine® Spinal Heavy; Astra, Sodertalje, Sweden) and Group V receiving the same bupivacaine DOSE AND 0.75 microgram/kilogram of body weight dexmedetomidine intravenously. Dexmedetomidine 100 µg/mL was mixed with preservative-free normal saline to 10 µg/mL. The 0.5 mL of dilute dexmedetomidine was added to the bupivacaine in group T. An independent investigator prepared the drug solutions and provided the coded drug to the anaesthetic administrator before the start of the anaesthesia. The anaesthetic administrator, patients, outcome assessors, and data analysts were blinded to the allocation. Spinal Anesthesia Patients were hydrated with 500 mL of 0.9% sodium chloride solution before anaesthesia. The spinal puncture was performed at L3-4 or L4-5 with a midline approach using a 25 G Quincke needle in the lateral decubitus position. After confirmation of free flow and clear cerebrospinal fluid, the drug was administered and the patients were then placed in the supine neutral position.

Assessment: The primary end-point of this study was the first request to analgesia. The secondary end-points were the total postoperative analgesic consumption as well as the VAS.
Crackers were provided during each of 3 treatment periods in a crossover design. The 3 types of crackers were matched for total carbohydrate content. Treatment period 1 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 4 (30g/day) for 7 days; Treatment period 2 (10 days): Participants received control crackers with 100% digestible starch; Treatment period 3 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 2 (30g/day) for 7 days. There were 5-day washout periods between the treatment periods.
Bladder cancer is a significant global health concern owing to its prevalence, negative impact on quality of life, and high treatment costs. Treatment for metastatic urothelial carcinoma (mUC) traditionally relies on platinum-based chemotherapy regimens. However, clinical trial results have led to the approval of immune checkpoint inhibitors (ICIs) as viable treatment options. We assessed the escalating costs and economic viability of mUC treatment guidelines in Europe. We used a pragmatic approach that involved: (1) collection of the costs of the recommended medications in the five most populous European countries; (2) conversion of the costs into international dollars to account for differences in purchasing power parity among countries; (3) evaluation of the cost trends over time; and (4) comparison of the medication costs to World Health Organization thresholds. Introduction of ICIs in European guidelines substantially increased the cost of medications for mUC. Intriguingly, important differences across European countries emerged: the annual cost of medications was twofold higher in Italy than in France and the UK. Despite limitations, our study sheds light on the escalating costs and economic challenges of mUC treatment, and highlights the need for assessments of sustainable and cost-effective management approaches. PATIENT SUMMARY: We looked at the costs of treatments for metastatic bladder cancer and found that costs have been rising over time, especially with the introduction of new immune therapies, with notable differences among European countries. While these new treatments improve patient outcomes, they also come with a high price tag, which could strain health care budgets. Our results suggest that cost-effectiveness studies will be essential in determining the best and most sustainable treatment strategies in the future.
Cold-inducible RNA-Binding Protein (CIRBP) is a general stress-response factor in vertebrates harboring two domains: an RNA-recognition motif and a regulatory domain rich in RG/RGG motifs. CIRBP has been described to bind mRNAs upon various stress conditions (cold, infections, UV, hypoxia …) and regulate their stability and translation. The proteins encoded by its targets are involved in key stress-responsive cellular pathways including apoptosis, inflammation, cell proliferation or translation, thus allowing their coordination. Due to its role in regulating central cellular functions, the expression of CIRBP is tightly controlled. We review here current understanding of the multiple mechanistic layers affecting CIRBP expression and function. Beyond transcriptional regulation by cold-responsive elements and the use of alternative promoters and transcription start sites, CIRBP undergoes various alternative splicing (AS) events which, depending on conditions, modulate the stability of CIRBP transcripts and/or impact the sequence of the encoded polypeptide. Typically, whilst CIRBP expression is induced in the context of hypothermia or viral infection, AS events preferentially address alternative isoforms towards mRNA degradation pathways in response to heat stress or to bacterial-secreted pore forming toxins. Post-translational modifications of CIRBP, mostly in its RGG domain, also condition CIRBP subcellular localization and access to its targets, thereby promoting or inhibiting their expression. For instance, phosphorylation and methylation events gate CIRBP nuclear to cytoplasmic translocation and control its recruitment to stress granules. Considering the therapeutic potential of modulating the expression and function of this central player in stress responses, a fine understanding of CIRBP regulation mechanisms deserves further attention.
OBJECTIVES: Living donor kidney transplantation (LDKT) is the preferred method of treatment for patients with end-stage kidney disease. Potential living kidney donors (PLKD) are evaluated through a thorough medical, psychological and surgical work-up to ensure successful transplantation with minimal risks to all parties involved. The transplant center at Rhode Island Hospital has noticed an increasing number of PLKDs excluded from donation due to conditions newly diagnosed during the screening process. Our objective is to understand the local trends underlying the high PLKD exclusion rates in the context of newly diagnosed conditions, age, race, and sex of the excluded donors.
STUDY DESIGN AND METHODS: Our study is a retrospective electronic medical record review of the 429 PLKDs screened at Rhode Island Hospital Kidney Transplant Center between December 2012 and April 2023. Age, race, gender, relationship to recipient, and reasons for exclusion were collected from the medical record for each PLKD.
CONCLUSION: 115 of the 429 total PLKDs screened were excluded for newly diagnosed conditions, the most common of which were renal issues (49%), diabetes mellitus (33%), and hypertension (13%), with many comorbid diagnoses. While these donors were able to receive proper treatment after their diagnosis, the earliest intervention possible yields the best prognosis. The high prevalence of treatable yet undiagnosed conditions raise many public health concerns, such as primary care gaps or discontinuous healthcare, and increases awareness about the importance of follow-up care for the excluded PLKDs.
PURPOSE: To obtain a denture stabilizer capable of reducing odor of raw materials and stimulating feeling to the gingiva by blending an extract from a safe natural material to a pasty system comprising vinyl acetate as a base material. CONSTITUTION: An extract from a tea leaves is blended to vinyl acetate as a base material. As a raw material of the extract, living leaves or dried leaves of tea can be used and crushed leaves can be preferably used. it is preferable to use 0.1-10.0wt.% extract of tea leaves based on the total weight. It is preferable to blend 30-80wt.% vinyl acetate resin. The denture stabilizer can be filled in a container such as an aluminum tube, a laminate tube, a plastic tube, etc.
An improved process for preparation of well-defined monodispersed colloidal particles of barium containing ferrites. This process involves the formation of colloidal barium ferrite particles in aqueous media by phase transformation of a ferrous hydroxide gel in the presence of barium ions. In this process, a magnetite is initially formed in aqueous solution and barium substituted into the resultant particle by displacement of Fe2+. This procedure is performed in a nonoxidizing atmosphere and under mildly caustic conditions. As the reaction proceeds to completion (aging) the system becomes decidedly more acidic. The colloidal particles produced in accordance with this invention are easily dispersible in aqueous media and, unlike magnetite, are superparamagnetic in response to a magnetic field. This procedure is in sharp contrast to more traditional methods of solid state transformations of the magnetite to ferrite at temperatures typically in excess of 1000°C.
Due to the COVID-19 pandemic and the consequent amendment to aid in the research response, study subjects with COVID-19 disease may participate in all aspects of this protocol, but depending on their disease state, infection timeline, and age, participation may be limited to only one component, procedure, and/or type of biospecimen collection. Age is a very important criteria, as pediatric subjects (5-17 years old) will only be eligible to participate in minimally invasive biospecimen collection procedures.
Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving evaluation, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure (FTDS), and a Satisfaction with Life Questionnaire. Driving Safety Education by a traffic safety professional, three x 1 hour sessions to discuss traffic safety rules regarding person, vehicle, environmental factors.
A human NKT cell line and use thereof in the preparation of a product for anti-tumor cellular immunotherapy. The human NKT cell line is named as NKT cell line 617, the preservation number is CCTCC NO: C2022121, and the preservation date is May 9, 2022. The NKT cell line 617 of the present invention is derived from the peripheral blood of a female NKTCL patient. The patient is negative for EBV infection, and the established cell line is also negative for EBV identification. The cell line being negative for EBV can be continuously subcultured in vitro for a long time, and has now been cultured in vitro for more than two years and monocloned successfully. The human NKT cell line that can be amplified in a large quantity depending on low-dose IL-2 provides a new tool experimental model for human NKT-related research and clinical adoptive immunotherapy.
FIELD: medicine, endocrinology. SUBSTANCE: method involves the use of phytotherapy and hirudotherapy carrying out for patient. Hirudotherapy is carried out by course of 8-20 treatments in 2-5 days by application of from 3 to 15 leeches for treatment on acupuncture points taken of group of projection of liver, spleen, adrenal glands, pancreas and thyroid and phytotherapy is carried out simultaneously or after termination of hirudotherapy for 1-3 months. Indicated phytotherapy involves intake of vegetable raw infusions comprising from 0.5 to 10% of medicinal sweet clover as measured for 15-30 g of dry raw per a daily dose. EFFECT: enhanced effectiveness of treatment. 4 cl, 3 ex
The SHARP study tests the feasibility, usability, and cultural relevance of an android application-supported walking study for brain health among older Black adults. The SHARP walking application enables the seamless integration of the brain-healthy behaviors of walking, social engagement, and reminiscence. Methods: Over the course of 24 weeks in the rapidly gentrifying historically Black neighborhoods of Portland, Oregon, triads aim to complete three 1-mile walks per week. The SHARP application is preprogrammed with 72 themed, 1-mile routes, accessible via a group tablet device. At three points along each route, GPS-triggered "Memory Markers" (historical images of local Black culture) appear on the walking application, serving as prompts for conversational reminiscence as triads walk. Walking reminiscence sessions are recorded for inclusion into a digital oral history archive.
The present invention relates to the field of cell engineering, and discloses a method for enhancing the activity of CIK cells. The method includes the culture of CIK cells in the presence of a DNA demethylation drug. The invention also discloses CIK cells and a preparation method thereof. The preparation method includes culturing peripheral blood mononuclear cells in the presence of cytokines for 9 to 11 days, and then culturing in the presence of a DNA demethylation drug. The invention also discloses the application of the CIK cells in the preparation of the preparation for the treatment of tumors. In addition, the invention also discloses the application of the DNA demethylation drug as a stimulating factor in enhancing the activity of CIK cells. The invention by the use of DNA demethylation drug significantly enhances the ratio of utility cells in CIK cells, significantly increase the killing activity of CIK cells on tumor cells, also can promote the proliferation activity of CIK cells, and has good clinical safety, no toxic or side effects, considerable overall anti-tumor effect, and great value in clinical application.
Mitochondrial Diseases (MD) are among the most frequent inherited metabolic diseases. Despite their high impact on patients, there are still no authorized drugs capable of modifying their clinical course. MD are clinically and genetically heterogeneous disorders, with muscular symptoms being one of their main manifestations. When muscular symptoms predominate, the disorder is classified as a Primary Mitochondrial Myopathy. In recent years, there have been significant advances in developing potential new treatments in this field. However, the absence of natural history studies makes the design and interpretation of clinical trials difficult and leads to long delays or even failures in the development of new treatments. The investigators propose to characterize in-depth a cohort of patients with Primary Mitochondrial Disorders due to mutations in the mitochondrial DNA (mtDNA) or in genes located in the nuclear genome (nDNA), from a clinical perspective but also a radiological, biochemical, and molecular point of view, and carry out a longitudinal follow-up of these parameters to identify those that are better correlated with severity and that allow measuring changes in the patient's clinical situation. With this objective, the investigators will analyze clinical variables (evaluation of motor function through manual force exploration, functional scales, and timed test, quality of life scales, serum biomarkers (growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21)), levels of heteroplasmy for cases harboring mtDNA mutations and mtDNA copy-number, and muscle magnetic resonance image of the lower extremities with quantification of fat replacement. All parameters will be evaluated at the beginning of the study and then annually during two years of follow-up.
Calcium Gluconate in Sodium Chloride Injection is a clear, colorless solution supplied in single-dose bags with an aluminum overwrap available as: 

*partial fill container 50 mL volume in a 100 mL container.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze. Product should be used within 60 days of removal from aluminum overwrap.

Preservative-free. Discard any unused portion in the single-dose bag immediately.